Compare

Twist Bioscience Corp vs ADMA Biologics, Inc. vs Repligen Corp vs Adaptive Biotechnologies Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearTwist Bioscience Corp
TWST
ADMA Biologics, Inc.
ADMA
Repligen Corp
RGEN
Adaptive Biotechnologies Corp
ADPT
Year ended2026-09-302025-12-312025-12-312025-12-31
Revenue$459.43M$510.17M$738.26M$276.98M
Revenue growth (YoY)+22.0%+19.6%+16.4%+54.8%
Gross margin52.4% (computed)57.4%52.3% (computed)74.2% (computed)
Operating margin-30.4%37.5%7.5%-20.6%
Net margin-28.3%28.8%6.6%-21.5%
Net income-$130.20M$146.93M$48.89M-$59.50M
EPS (Diluted)-$2.08$0.60$0.86-$0.39
Operating cash flow-$41.43M$50.40M$117.42M-$45.99M
Free cash flow-$89.01M$27.82M$93.90M-$48.95M
Cash & equivalents$533.99M$87.63M$566.02M$70.50M
Total assets$1.12B$624.24M$2.95B$512.74M
Total liabilities$233.79M$146.92M$843.57M$287.74M
Shareholders' equity$888.02M$477.32M$2.11B$218.79M
Return on year-end equity-14.7%30.8%2.3%-27.2%
Shares outstanding67.81M237.87M56.33M153.78M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearTwist Bioscience CorpADMA Biologics, Inc.Repligen CorpAdaptive Biotechnologies Corp
Latest$459.43M
Ended 2026-09-30
$510.17M
Ended 2025-12-31
$738.26M
Ended 2025-12-31
$276.98M
Ended 2025-12-31
1 year earlier$376.57M
Ended 2025-09-30
$426.45M
Ended 2024-12-31
$634.44M
Ended 2024-12-31
$178.96M
Ended 2024-12-31
2 years earlier$312.97M
Ended 2024-09-30
$258.21M
Ended 2023-12-31
$632.36M
Ended 2023-12-31
$170.28M
Ended 2023-12-31
3 years earlier$245.11M
Ended 2023-09-30
$154.08M
Ended 2022-12-31
$801.54M
Ended 2022-12-31
$185.31M
Ended 2022-12-31
4 years earlier$203.56M
Ended 2022-09-30
$80.94M
Ended 2021-12-31
$670.53M
Ended 2021-12-31
$154.34M
Ended 2021-12-31